Infantile leukemia-What factors determine its distinct biological nature? Clinicopathological study of 78 cases.
Liu, X; Zhao, Y; Luedke, C; Jug, R; Yang, LH; Lu, M; Pan, Z; Wang, D; Lorsbach, R; Shi, Y; et al.
International Journal of Laboratory Hematology.
2021;
43:1117-1122.
Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency.
Wortmann, SB; Zietkiewicz, S; Guerrero-Castillo, S; Feichtinger, RG; Wagner, M; Russell, J; Ellaway, C; Mróz, D; Wyszkowski, H; Weis, D; et al.
Genetics in Medicine.
2021;
23:1705-1714.
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).
Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al.
Blood Cells, Molecules, and Diseases.
2021;
87.
VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects.
Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al.
American Journal of Human Genetics.
2020;
107:1149-1156.
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.
Lee, LH; Krupski, C; Clark, J; Wunderlich, M; Lorsbach, RB; Grimley, MS; Burwinkel, M; Nelson, A; Kumar, AR.
Blood Advances.
2020;
4:717-727.
Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR).
Niss, O; Lorsbach, RB; Buchbinder, DK; Chonat, S; McLemore, ML; McCavit, T; Schwartz, JH; Meznarich, J; Seu, K; Zhang, W; et al.
Blood.
2019;
134:3521-3521.
Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
Sopfe, J; Endres, A; Campbell, K; Hayes, K; Trout, AT; Liang, X; Lorsbach, R; O'Brien, MM; Cost, CR.
Pediatric Blood and Cancer.
2019;
66.
Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.
Knez, V; Liu, X; Schowinsky, J; Pan, Z; Wang, D; Lorsbach, R; Lu, C; Luedke, C; Haag, M; Carstens, B; et al.
Leukemia and Lymphoma.
2019;
60:1006-1013.
Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis.
Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al.
Pediatric Blood and Cancer.
2018;
65.
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
Lee, LH; Gasilina, A; Roychoudhury, J; McCormack, FX; Pressey, J; Grimley, MS; Lorsbach, R; Ali, S; Bailey, M; Stephens, P; et al.
JCI insight.
2017;
2.